SUSMED,Inc.
4263・Growth Market・Information & Communication
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 7 members (4 outside, 3 internal), with an outside director ratio of approximately 57%. A Governance Committee (majority independent outside directors) has been established to deliberate on nominations and compensation. The Audit and Supervisory Committee consists of 3 members, all of whom are outside directors.
Risk Management
Based on the Risk Management Regulations, the Risk Management Committee, chaired by the Representative Director and President, meets once per quarter to assess and monitor risks relating to markets, information security, the environment, labor affairs, product quality, and other areas, and reports to the Board of Directors. The Company has obtained and maintains ISMS (ISO27001) certification, and updates its Business Continuity Plan (BCP) and conducts in-house training once per year. In the event of an emergency, a countermeasure headquarters is established, with a system in place to coordinate with external experts.
Shareholder Returns
Continuing a no-dividend policy. The forecast annual dividend for FY2026 (ending June 2026) is ¥0. The company prioritizes securing funds for upfront investment in R&D and does not plan to pay dividends for the time being. No share buybacks or shareholder benefit programs are being implemented.
Dividend Policy
The company prioritizes securing funds to support the continuous and planned execution of R&D activities, and does not plan to pay dividends for the time being. The annual dividend is ¥0 for both FY2025 (ending June 2025) and FY2026 (ending June 2026). Going forward, the company will consider distribution of surplus while taking into account its business performance and financial condition.
ESG
With the mission of 'Realizing Sustainable Medicine,' the company positions the reduction of environmental burden and the resolution of healthcare challenges through the provision of therapeutic apps and general-purpose clinical trial systems as the core of its E (Environment) domain. In the S (Social) domain, it has introduced full-flex remote work, achieved a 100% health checkup and stress check participation rate for three consecutive fiscal periods, and improved the turnover rate for employees with less than one year of tenure from 23.08% to 9.09%. In the G (Governance) domain, there were zero material compliance violations, ISMS certification has been maintained, and BCP updates and drills are conducted once a year. A process has been established whereby materiality is deliberated on and approved by the Board of Directors with reference to SASB, GRI, and the SDGs.
Last updated: September 26, 2025